Clinical trials: Graft Rejection
Acute Graft Rejection, Chronic Allograft Nephropathy
Study Cyclosporine (CsA) Versus Tacrolimus (Tacro) After Campath Induction in Kidney Transplantation
After alemtuzumab induction, followed with kidney transplantation, patients will be randomly assigned to receive either tacrolimus or cyclosporine microemulsion in combination with mycophenolates.
- Conditions
- Acute Graft Rejection, Chronic Allograft Nephropathy, Polyomavirus-related Transplant Nephropathy
- Trial name
- RSCS-Campath (NCT01346397)
- Testing
- cyclosporine or tacrolimus
- Where
- Russia
- Volunteers
- 170 people
- Sponsor
- Russian Academy of Medical Sciences
Graft Rejection, Kidney Disease
Effectiveness of the Investigational Drug Campath-1H in Preventing Rejection of Transplanted Kidneys
This protocol will test a humanized monoclonal antibody known as Campath-1H for its ability to induce a state of permanent allograft acceptance, or tolerance, when administered in combination with a brief course of the…
- Trial name
- NCT00001984
- Testing
- Alemtuzumab and DSG
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hematologic Malignancies, Bone Marrow Transplant Rejection
Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies
This study will evaluate the safety and effectiveness of stem cell transplantation in which the donor's T cells (a type of lymphocyte, or white blood cell) are removed and then added back.
- Trial name
- NCT00079391
- Testing
- allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)